Literature DB >> 2261600

Intrinsic B lymphocyte defect in untreated patients with Hodgkin's disease.

F Griesinger1, L Bergmann, R Barot-Ciorbaru, P S Mitrou.   

Abstract

In vivo and in vitro humoral and cell-mediated immunological defects have been described in untreated patients with Hodgkin's disease (HD). The cellular basis of the recently described in vitro reduction of mitogen-induced immunoglobulin synthesis has not been elucidated so far. In this study, we attempted to dissect T and B lymphocyte function in untreated HD patients. Mitogen-induced in vitro immunoglobulin synthesis was assessed in the presence of pokeweed mitogen, the mitogenic anti-CD3 monoclonal antibody OKT3 and the relatively T-cell-independent B cell mitogen Nocardia opaca delipidated mitogen (NDCM). Mitogen-induced Ig synthesis by HD peripheral blood mononuclear cells was significantly reduced compared to that in control peripheral blood mononuclear cells. In coculture assays, T cells of HD patients exerted an adequate helper function to control B cells. However, normal donor T cells did not restore Ig synthesis by B cells of HD patients. Finally, B cells of HD patients were unresponsive to NDCM, which is able to induce Ig synthesis in control B cells even in the absence of T cells. These data provide evidence for an intrinsic functional B lymphocyte defect in HD patients, and suggest that increased activation of suppressor HD T lymphocytes may not play a significant role in the suppression of in vitro Ig synthesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2261600     DOI: 10.1007/bf01741710

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  32 in total

1.  In vitro lymphocyte response to the phytomitogens in untreated and treated patients with Hodgkin's disease.

Authors:  S Romagnani; A Amadori; G Biti; G Bellesi; M Ricci
Journal:  Int Arch Allergy Appl Immunol       Date:  1976

Review 2.  Functional and molecular aspects of human T lymphocyte activation via T3-Ti and T11 pathways.

Authors:  A Alcover; D Ramarli; N E Richardson; H C Chang; E L Reinherz
Journal:  Immunol Rev       Date:  1987-02       Impact factor: 12.988

3.  Enhancement of natural killer cell activity by Nocardia opaca fractions.

Authors:  R Barot-Ciorbaru; T J Linna; M R Patel; J Altman; C Carnaud
Journal:  Scand J Immunol       Date:  1989-02       Impact factor: 3.487

Review 4.  Modulation of immune responses by Nocardia immunostimulants.

Authors:  C Bona
Journal:  Prog Allergy       Date:  1979

5.  Delayed-type hypersensitivity and the immunology of Hodgkin's disease, with a parallel examination of sarcoidosis.

Authors:  M W Chase
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

6.  Defective in vitro antibody production to Varicella zoster and other virus antigens in patients with Hodgkin's disease.

Authors:  R L Souhami; J Babbage; A Sigfusson
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

7.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

8.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells.

Authors:  T Uchiyama; D L Nelson; T A Fleisher; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Spectrum of immunodeficiencies with Hodgkin's disease.

Authors:  J J Twomey; A H Laughter; L Rice; R Ford
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

10.  Blood B and T lymphocytes and in vitro cellular immune reactivity in untreated human malignant lymphomas and other malignant tumors.

Authors:  H E Heier; R Klepp; S Gundersen; T Godal; T Normann
Journal:  Scand J Haematol       Date:  1977-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.